Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral mol…
Biotechnology
US, Boston [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Monte Rosa Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -2.2200 | -2.403 | 0 | 3 | -104 | -119 | -99 | 0 | -120 | 0 | 27 | 0 |
| 2024 | -2.6300 | -1.006 | 0 | 66 | -135 | -52 | -137 | 0 | -149 | 0 | 32 | 0 |
| 2025 | - | -1.545 | - | 24 | - | -77 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F31/td> | - | 2.F31 | - | 2.F31 |
| 2027 | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2028 | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |